<DOC>
	<DOCNO>NCT01911676</DOCNO>
	<brief_summary>This study involve interlinked design determine dose associate optimal activity occupancy Glyt1I PF-03463275 healthy subject schizophrenia subject test dose combination cognitive remediation treatment cognitive impairment Schizophrenia .</brief_summary>
	<brief_title>Translational Neuroscience Optimization GlyT1 Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>1 ) Males females 21 55 year age ( inclusive ) . 3 ) Able provide write informed consent . 4 ) Only CYP2D6 extensive metabolizers . 1 ) No ongoing acute medical issue 2 ) Clinically significant ECG abnormality 3 ) Blood donation within eight week start study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>